Raymond James analyst Laura Chico notes that the Brazilian Supreme Court of Justice has broken Alexion's Soliris method of use patent covering the treatment of paroxysmal nocturnal hemoglobinuria. The analyst estimates Brazilian revenue comprises about 5% of the company's total revenue. Given the concerns this move will trigger on orphan drug pricing flexibility, Chico thinks it is important to consider that there is no known imminent biosimilar Soliris launches in Brazil. Her estimates remain unchanged as she awaits further clarity. The analyst reiterates an Outperform rating on the shares.